pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$NUVBNuvation Bio Inc.

$NUVB3.8400-3.76%
New York, NY, USupdated 13h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 3: 1Marketed: 1
1Phase 31Marketed
Marketed
taletrectinib adipate
Solid Tumor
Phase 3
safusidenib
Malignant Glioma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 2, 2026
earnings
$NUVB3.8400-3.76%
15d ago
Nuvation Bio Inc. earnings
Nuvation Bio Inc.
→
view all catalysts →

Active trials

  • phase2Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Diseasenot yet recruitingn=40
  • phase1Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinibnot yet recruitingn=56
  • phase3SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)recruitingn=365
  • phase3Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)recruitingn=180
  • phase3A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patientsrecruitingn=194
  • phase2A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Geneactive not recruitingn=173
  • phase2Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusionterminatedn=14
  • phase2Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumorsactive not recruitingn=466
🐶 Hiring Signal
No open roles indexed yet — view Nuvation Bio Inc. jobs →

News

  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    stat · 17d ago
  • ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
    Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and C…
    biospace · 1mo ago
  • Chutes & Ladders—Vir looks to Liu to lead late-stage push
    As Vir pushes its lead hepatitis D combo through phase 3 development, the biotech has tapped an experienced medical expert to light the way. David Liu, M.D., Ph.D., is now Vir’s chief medical offic…
    fiercebiotech · 1mo ago
  • Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
    onclive · 6mo ago
identifiers
ticker
$NUVB
SEC CIK
0001811063
country
US
source
sec_tickers
top tags
Oncology2NSCLC1
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?